AB SCIENCE news, videos and press releases - Page 3
For more news please use our advanced search feature.
AB SCIENCE - More news...
AB SCIENCE - More news...
- AB Science announces a voluntary hold in the clinical studies of masitinib worldwide
- AB Science will host a live webcast on Tuesday May 25, 2021 on masitinib results in Prostate Cancer
- AB Science reports today its annual financials as of 31 December 2020 and provides an update on its activities
- AB Science today announced that its masitinib Phase 2B/3 study (AB12003) in metastatic castrate-resistant prostate cancer (mCRPC) met its predefined primary endpoint
- AB Science secures 6M€ in non-dilutive financing guaranteed by the French Government
- AB Science provides an update on the expected timelines for the read-out of its masitinib Phase 3 study (AB12003) in metastatic castrate-resistant prostate cancer
- AB Science issues a corrective press release regarding adverse events information from study AB09004 reported on December 16, 2020
- AB Science will host a live webcast on Friday December 11, 2020 on masitinib’s results in pancreatic cancer
- EIB supports AB Science in its COVID-19 development programme
- AB Science announces a financing of 4.5 million euros through the issuance of bonds convertible into new ordinary shares
- AB Science announces that results from masitinib study AB07015 in severe asthma have been selected for presentation at an ATS symposium held on 16th October, 2020
- AB Science to present results from its Phase 3 AB07015 study in severe asthma at the annual European Respiratory Society International Congress
- AB Science to present results from its Phase 2B/3 AB07002 study in progressive forms of multiple sclerosis at MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting
- AB Science announces that new results published in the peer-reviewed Journal of Alzheimer's Disease support masitinib’s potential mode of action in Alzheimer’s Disease
- AB Science announces that results from AB8939 preclinical program in acute myeloid leukemia will be presented at the European Hematology Association 2020 Annual Congress
- AB Science granted authorization by ANSM to initiate Phase 2 study evaluating masitinib in combination with isoquercetin for the treatment of COVID-19
- AB Science reports today its annual financials as of 31 December 2019
- AB Science will present results from its Phase 3 AB07015 study in severe asthma at the 2020 American Thoracic Society International Conference
- AB Science is providing a summary of the live webcast held on 06 March 2020 with key opinion leaders in progressive forms of multiple sclerosis
- AB Science will host a live webcast on masitinib in Progressive Forms of Multiple Sclerosis on Friday March 06, 2020
- AB Science will host a live webcast on masitinib in Progressive Forms of Multiple Sclerosis on Friday March 06, 2020
- AB Science announces positive top-line Phase 2B/3 results for oral masitinib in progressive forms of multiple sclerosis
- AB Science announces that FDA green-lights U.S. patient enrollment in masitinib Phase 3 study following IND clearance in metastatic castrate-resistant prostate cancer eligible to chemotherapy
- AB Science announces the publication of new results in the peer-reviewed journal Glia that further support masitinib’s potential mode of action in ALS
- AB Science provides the summary of webcast with Key Opinion Leaders on masitinib Phase 3 results in severe asthma uncontrolled by oral corticosteroids
- AB Science will host a live webcast on masitinib in severe asthma on Monday December 2, 2019
- AB Science announces positive top-line Phase 3 results for oral masitinib in severe asthma
- AB Science granted authorization to initiate phase 3 confirmatory study of masitinib in indolent systemic mastocytosis
- AB Science today reports its revenues for the first half of 2019 and provides an update on its activities.
- AB Science annouces the success of a private placement
